TICKERNERD
Menu
EVMNEVMNHealthcare · Biotechnology

EVMN Stock Forecast: Evommune, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$12
+3.02% on the day

The 10 Wall Street analysts covering Evommune, Inc. hold a median 12-month price target of $28 — +141.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$405.2M
Ticker Nerd rank
17 / 100
Median analyst target
$28
Analysts covering
10
Total return, dividends reinvested
1W
+1.0%
1M
−10.6%
YTD
−32.3%
From high
−63.3%
From low
+4.9%
$11
$32
Range since 6 Nov 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

EVMN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Evommune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
63
Issuance
63
Size
56
Quality
43
Value
37
Accruals
16
Growth
8
Momentum
3
Volatility
3

Revisions (63): Analysts have, on balance, been raising their forecasts.

Volatility (3): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Evommune, Inc. — and when they’d sell — is the membership.

Wall Street

EVMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EVMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Nov 2025Adjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26EVMNHigh $54Median $28Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $22Median $28High $54

The green dot is the last close — the median target sits +141.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
30 June 2026HC Wainwright & Co.DowngradeNeutral—
30 June 2026HC Wainwright & Co.DowngradeNeutral—
30 June 2026Morgan StanleyMaintainsOverweight$55 → $26
30 June 2026Morgan StanleyMaintainsOverweight—
29 June 2026William BlairDowngradeMarket Perform—
29 June 2026William BlairDowngradeMarket Perform—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026Morgan StanleyMaintainsOverweight—
10 Apr 2026RBC CapitalReiteratesOutperform—
18 Mar 2026Clear StreetInitiatesBuy—
18 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026OppenheimerInitiatesOutperform—
8 Jan 2026Raymond JamesInitiatesStrong Buy—
6 Jan 2026HC Wainwright & Co.InitiatesBuy—
1 Dec 2025Cantor FitzgeraldInitiatesOverweight—
1 Dec 2025Evercore ISI GroupInitiatesOutperform—
1 Dec 2025Leerink PartnersInitiatesOutperform—
1 Dec 2025Morgan StanleyInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

EVMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Evommune, Inc. (EVMN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
40.5×

Cheaper than 6% of US stocks

Price / book
1.3×

Cheaper than 62% of US stocks

EV / EBITDA
−2.3×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−899.9%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.0%

Higher than 22% of US stocks

Return on assets
−29.7%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EVMN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EVMNEvommune, Inc.$405.2M
17
PBYIPuma Biotechnology, Inc.$403.6M
100
LRMRLarimar Therapeutics, Inc.$403.4M
33
OVIDOvid Therapeutics, Inc.$414.3M
64
STROSutro Biopharma, Inc.$396.1M
77
EDITEditas Medicine, Inc.$395.9M
53
OCGNOcugen, Inc.$416.4M
28
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVMN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest EVMN news & analysis

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Business Wire · 30 July 2026positive

Evommune announced the first patient was dosed in its Phase 2b clinical trial of EVO756, an oral small molecule MRGPRX2 inhibitor, for the prophylactic treatment of migraine.

Why it matters — This milestone advances a key pipeline candidate into later-stage clinical testing for a new indication, expanding Evommune's potential therapeutic reach beyond inflammatory diseases.

FAQ

Frequently asked questions about EVMN stock

What is the EVMN stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Evommune, Inc. have a median 12-month price target of $28, with estimates ranging from $22 to $54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EVMN stock a buy right now?

Of the 10 analysts covering Evommune, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evommune, Inc. 17 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EVMN?

As at 1 Aug 2026, Evommune, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).

Will EVMN stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +141.6% from the last close, and Ticker Nerd's factor model ranks Evommune, Inc. 17 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EVMN stock forecast for 2030?

No analyst covering Evommune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $54 over the next 12 months.

What does Evommune, Inc. do?

Evommune, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for immune-mediated chronic inflammatory diseases.

What is the latest news on EVMN?

The most recent item we track (Business Wire, 30 July 2026): "Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis". Evommune announced the first patient was dosed in its Phase 2b clinical trial of EVO756, an oral small molecule MRGPRX2 inhibitor, for the prophylactic treatment of migraine.

Company

About Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for immune-mediated chronic inflammatory diseases. Founded in 2020 and headquartered in Palo Alto, California, Evommune aims to create innovative treatments that address major unmet medical needs in conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company’s product candidates, EVO756 and EVO301, are currently in Phase 2 clinical trials, targeting both symptomatic relief and the underlying drivers of chronic inflammation. By leveraging advanced scientific research and a seasoned management team with deep expertise in immunology and drug development, Evommune, Inc. is positioned to contribute meaningfully to the rapidly evolving biopharmaceutical landscape. As a publicly listed entity, the company provides investors access to a specialized segment of the healthcare sector, reflecting broader investor interest in innovative biotech firms addressing chronic disease burden.

CEO Mr. Luis C. Pena · 48 employees · United States · https://www.evommune.com